{
  "symbol": "ARCT",
  "company_name": "Arcturus Therapeutics Ltd",
  "ir_website": "https://ir.arcturusrx.com/",
  "structured_data": [
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Governance Highlights",
          "url": "https://ir.arcturusrx.com/governance-highlights",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Governance Highlights \n\n## Corporate Governance Overview\n\nThe Board of Directors of Arcturus (the \"Company\") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations. \n\n## Governance Documents\n\n  * ### Code of Business Conduct and Ethics\n\n[Code of Business Conduct and Ethics](/static-files/d91a5916-5ba8-450b-9a87-11c2b87daf0a \"01 - ARCT-Policy Code of Business Conduct and Ethics 6Dec21.pdf\") 324.6 KB\n\n\n\n\n## Governance Charters\n\n  * ### Nominating and Corporate Governance Committee Charter\n\n[Nominating and Corporate Governance Committee Charter](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77 \"Arcturus Holdings - Nominating and Corporate Governance Committee Charter\\(110996118_3\\).pdf\") 232 KB\n\n  * ### Audit Committee Charter\n\n[Audit Committee Charter](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f \"Arcturus Holdings - Audit Committee Charter\\(110996116_3\\).pdf\") 136.9 KB\n\n  * ### Compensation Committee Charter\n\n[Compensation Committee Charter](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab \"Arcturus Holdings - Compensation Committee Charter\\(110996117_3\\).pdf\") 213.3 KB\n\n\n\n\nSearch * Submit\n"
        },
        {
          "title": "Management Team",
          "url": "https://ir.arcturusrx.com/corporate-governance/management-team",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Management Team \n\n  * ###  Joseph E. Payne, MSc \n\n![Joseph Payne, MSc](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/3-36-43/portrait-joseph-e-payne%20new.jpg?itok=221uEdTj)\n\nPresident & CEO, Director of the Board\n\nJoseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics, Inc. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.\n\n  * ###  Dr. Pad Chivukula \n\n![Dr. Pad Chivukula](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2022/04/21/15-38-09/Pad%20Chivukula%2090x90.jpg?itok=hTtbdR_5)\n\nChief Scientific Officer and Chief Operating Officer\n\nDr. Pad Chivukula is the co-founder of Arcturus Therapeutics and has served as the Chief Scientific Officer and Chief Operating Officer since 2013. With a deep foundation in nanoparticle technology, Dr. Chivukula leads Arcturus in discovering and developing transformative medicines for diseases with unmet needs. Since Arcturus’ founding, he has built and advanced the company’s research competencies and pipeline in the areas of RNA therapeutics and vaccines, integrating advanced therapeutic platforms, and streamlining innovative processes. Dr. Chivukula holds over 100 publications and patents.\n\nPrior to Arcturus, Dr. Chivukula held key roles at Nitto, including Group Leader and Chief Scientist, where he led the polymeric RNAi research department. He holds a Ph.D. in Pharmaceutical Chemistry from the University of Utah, specializing in nanoparticle technology.\n\n  * ###  Andrew Sassine, MBA \n\n![Andrew Sassine](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/3-37-32/andy_sassine_color2%20new.jpg?itok=ijqim5kL)\n\nChief Financial Officer\n\nAndy Sassine is currently, and has been since January 2019, the Chief Financial Officer at Arcturus Therapeutics. He also serves on the Board of Directors of Nasdaq listed ICAD Inc. ICAD Inc. is a leading provider of advanced image analysis, workflow solutions and radiation therapy for early detection and treatment of cancer. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2005 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors from 2009 to 2018. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.\n\n  * ###  Lance Kurata \n\n![lance](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/09/10/12-40-09/Lance%20Kurata%20Chief%20Legal%20Officer_final.png?itok=u4EDIVMg)\n\nChief Legal Officer\n\nLance Kurata has served as the Chief Legal Officer of Arcturus Therapeutics since August 2020. Prior to Arcturus, from 2006 to 2020, Mr. Kurata was a partner at Mintz Levin and Chair of the West Coast Technology Transactions Practice. From 2002 to 2006, he was a partner at Fish & Richardson, where he was a member of the corporate group and nationwide head of the technology transactions practice. From 1996 until 2002, Mr. Kurata practiced corporate law at Brobeck Phleger & Harrison, specializing in strategic collaborations, public and private financings, mergers and acquisitions and corporate governance. Mr. Kurata is licensed to practice law in the State of California. He received his Juris Doctor (JD) degree from Stanford Law School and was an editor of Stanford Law Review.\n\n  * ###  Kevin Skol \n\n![Kevin Skol](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2023/01/09/11-38-59/Kevin%20Skol%2C%20252px.jpg?itok=ad0DECiF)\n\nChief Business Officer\n\nKevin Skol has 20 plus years of experience in the pharmaceutical industry, primarily in business and corporate development, alliance management, strategy, competitive intelligence, and licensing. He previously worked at RNA based companies Ionis Pharmaceuticals and Digital Gene Technologies and at specialty pharmaceutical companies Elan Corporation and Valeant Pharmaceuticals. At Ionis he led business development and licensing efforts that resulted in major pharmaceutical partnerships with Astra Zeneca, Bayer, Roche, Janssen, Novartis, and Biogen. Most recently he led the Arcturus business development team in the closing of several vaccine collaborations with the Vingroup in Vietnam, Israel and CSL Seqirus. The combined transaction value of collaborative agreements and partnerships which he led throughout his career is estimated at over $4 billion. Mr. Skol previously served on the board of directors at Ingredient Innovations International (3i) which was subsequently acquired. Mr. Skol graduated with a B.A. from Yale University and has an MBA from Harvard Business School.\n\n  * ###  Juergen Froehlich \n\n![Juergen Froehlich](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2023/05/16/13-13-07/Juergen%20Froehlich%2090px.jpg?itok=TpyJzYC5)\n\nChief Medical Officer\n\nJuergen’s career spans three decades and covers a broad therapeutic range of planning and hands-on execution of nonclinical and all phases of clinical drug development such as cystic fibrosis, bronchiectasis, acromegaly, OTC deficiency, cervical dystonia, acute stroke, acute coronary syndrome and diabetic nephropathy. He has worked with biologics, macrocycles, peptides, small molecules and RNA therapeutics at small, mid-size and large companies, like Boehringer Ingelheim, Genentech, Quintiles, Bristol-Myers-Squibb, Ipsen, Vertex, Aradigm Corporation, Genevant and EnBiotix Inc/Spexis AG. In several assignments as Chief Medical or Chief Development Officer, he actively participated in successful fundraising activities. Juergen was instrumental in critical regulatory interactions and obtaining marketing authorizations in the U.S., Canada, the E.U., Switzerland and Australia. He is a board member of Appili Therapeutics in Canada, a public company focusing on prevention and treatment of a broad spectrum of infectious diseases. At Genevant, Juergen created the clinical development programs plans to utilize mRNA or siRNA molecules for OTC deficiency, acromegaly and RNA targets for other liver diseases. He also oversaw the toxicology programs for these development projects. At Vertex, as Head of Regulatory Affairs and Clinical Regulatory Strategy, Juergen hands-on supported the NDA, MAA and other regulatory submissions/approvals for Kalydeco® and participated in regulatory interactions with the FDA on development planning for follow-on CFTR modulators. Since 2013 he has been involved in early and late-stage development of inhaled therapeutics, including the planning and conduct of Ph 1-3 trial programs with colistin, murepavadin and liposomal ciprofloxacin in patients with cystic fibrosis (CF) or bronchiectasis and chronic Pseudomonas aeruginosa lung infection. He was an invited panel member at a U.S. Food and Drug Administration workshop in 2018 for inhaled antibiotics in CF and bronchiectasis. Juergen earned his MD from Wuerzburg University in Germany and his dual executive MBA degree from the Graduate School of Business Administration in Switzerland and the State University of New York at Albany. He is a Fellow of the American College of Clinical Pharmacology and a diplomate of the American Board of Clinical Pharmacology.\n\n  * ###  Igor Smolenov \n\n![Igor Smolenov](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2023/05/16/13-12-06/IgorSmolenov%2090px.jpg?itok=rSBRxe7E)\n\nChief Development Officer\n\nIgor Smolenov is the Chief Development Officer of Arcturus Therapeutics. Dr. Smolenov is a recognized leader in clinical development with a proven record of accomplishment in small biotechnology and large pharmaceutical companies. He contributed to the successful development and licensure of several innovative vaccines. Before joining Arcturus, Dr. Smolenov was the Executive Vice President at Clover Pharmaceuticals, where he built a strong team able to rapidly generate pivotal clinical data leading to COVID-19 vaccine authorization and the product launch. Before that, Dr. Smolenov served as Therapeutic Area Head, leading the development of several seasonal influenza vaccines in Seqirus (CSL), and Head of Clinical Development in Moderna Therapeutics, managing the initiation of the first clinical trials of mRNA vaccines in humans. At Novartis Vaccines, Dr. Smolenov contributed to the development and global licensure of meningococcal vaccines (Menveo®, Bexsero®, and MenABCWY) and the overall commercial success of the meningococcal vaccines franchise. Igor Smolenov graduated from Volgograd State Medical University, Russia, and holds MD, Ph.D., and Doctor of Science (D.Sc.) (Habilitation) degrees from this university. Before starting his industry career, he passed multiple academic steps from junior researcher to professor and head of the Allergy/immunology department of the university. He is the author of more than 50 publications in peer-reviewed journals in clinical pharmacology, infectious diseases, and vaccine development.\n\n  * ###  Natash O. Bowman \n\n![Natasha Bowman](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2023/08/17/15-25-07/Natasha%20Bowman%20317px.jpg?itok=ymvD_kix)\n\nChief Human Resources Officer\n\nNatasha O. Bowman is the Chief Human Resources Officer at Arcturus Therapeutics, where she oversees the overall human resources function for the global late-stage clinical messenger RNA medicines and vaccines company. During her time at Arcturus Therapeutics, employee headcount has doubled and through this expansion amidst the COVID-19 pandemic, she played a vital role of supporting the rapid addition of the COVID-19 program. She has more than 25 years of experience in the field of Human Resources with robust industry and leadership experience in the pharmaceutical, medical device, manufacturing, and public sectors. Ms. Bowman most recently was the Senior Vice President of Human Resources at Synthetic Genomics for over 7 years where she served as a strategic adviser providing guidance on all HR related matters to the CEO, Board of Directors, and other members of the executive team. She previously held positions in start-up, mid-size, and Fortune 500 companies including Althea Technologies, ACADIA Pharmaceuticals and Pfizer Inc. where she played a key role in the start-up, growth, and mergers & acquisitions of those organizations. Ms. Bowman received a B.S in Business Management from San Diego State University. She was named as one of San Diego’s 500 Most Influential Business Leaders by the San Diego Business Journal in 2018, 2019, and 2020. She was also named as one of the Top HR & Diversity Professionals in 2023 by the San Diego Business Journal. She is on the Board of Directors for the non-profit organizations San Diego Girl Scouts, San Diego HR Forum, and Friends of Music.\n\n  * ###  Ye Zhang \n\n![Ye Zhang](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2024/04/29/13-18-09/Ye%20Zhang_180px.png?itok=jCicga2M)\n\nChief Regulatory Officer\n\nYe Zhang is the Chief Regulatory Officer for Arcturus Therapeutics, where she establishes Regulatory Affairs department and oversees the Regulatory Strategy, Regulatory CMC, Regulatory Operation and Labeling to support the development of vaccines and rare disease therapeutics. Under her leadership, the team successfully supported the COVID-19 Vaccine NDA filing with the PMDA, leading to Arcturus' first drug product approval and the world's inaugural approval of a self-amplifying mRNA vaccine. Dr. Zhang has more than 20 years of experience in regulatory and drug development for vaccines, biologics and small molecules. Prior to joining Arcturus Therapeutics, Dr. Zhang held various roles of increasing responsibility at Merck, where she was responsible for more than ten vaccines in development and life-cycle management and had extensive experience in working with FDA, EMA, PMDA, MHRA, NMPA and other regulatory authorities. She also worked at FDA where she reviewed more than 60 drug applications and gained extensive regulatory experience. Dr. Zhang received a Ph.D. in Pharmaceutical Sciences from the University of Colorado, and an M.D. from the Medical School of Peking University. Dr. Zhang is a lifetime member of the Food and Drug Administration Alumni Association (FDAAA) and serves as a board director for Alliance for mRNA Medicine (AMM). Recognized for her achievements, she was named as one of the Top 25 Healthcare Technology Leaders of Pennsylvania for 2023.\n\n  * ###  Roberta Duncan \n\n![Roberta Duncan](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2024/04/29/13-17-24/Roberta%20Duncan_180px.png?itok=cLnSEUZX)\n\nChief Strategy Officer\n\nRoberta Duncan is the Chief Strategy Officer at Arcturus Therapeutics and has been in the biopharma industry for more than 26 years with experience from start-up and small biotech to pharma and CROs. She is currently the Board Vice-Chair of the Alliance for mRNA Medicines (AMM) and previously held the role of Vice President leading CSL’s enterprise-wide mRNA Program. Roberta has led complex programs, driving profitable growth, enhancing productivity, accelerating critical growth assets into the pipeline, leading revenue generating products, and enabling commercial launch and market expansion. Roberta has an extensive and diverse background across multiple therapeutic areas and business functions, inclusive of strategy, business development, business planning and operations, governance, portfolio and program management, program leadership, alliance management, R&D (including clinical development, regulatory, clinical operations, R&D systems and compliance), and product development. Her experience spans across industry-leading organizations such as CSL, Eli Lilly, Bristol Myers Squibb, Shire Pharmaceuticals (acquired by Takeda), Trevi Therapeutics, Kendle International (acquired by Syneos), and Quintiles (now IQVIA).\n\nRoberta earned her BA in Biochemistry from New York University, as well as two MBAs in International Management and Strategy from Krannert School of Management (Purdue University) and TiasNimbas Business School (Tilburg University, The Netherlands).\n\n\n\n\nSearch * Submit\n"
        },
        {
          "title": "Board of Directors",
          "url": "https://ir.arcturusrx.com/corporate-governance/board-of-directors",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Board of Directors \n\nDr. Peter Farrell \n\nChairman\n\n![Dr. Peter Farrell](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/12-13-38/Peter_Farrell_color.jpg?itok=nJZyKytO)\n\nDr. Peter Farrell is the founder, former long-term CEO and current Chairman of ResMed (NYSE:RMD). Farrell has been Chairman and a director of ResMed since 1989, when the company began as a management buyout of sleep technology from Baxter Healthcare. Peter was previously Foundation Director of the University of New South Wales (UNSW) Graduate School for Biomedical Engineering (1978-89) while simultaneously serving as Vice President of Research & Development for Baxter Healthcare in Tokyo (1984-89). He is also on the board of trustees of The Scripps Research Institute in La Jolla and is Chairman of the Boston-based POC NMR diagnostic company, WaveGuide. Dr. Farrell is a fellow or honorary fellow of several professional bodies, including the US National Academy of Engineering. He was inducted as 1998 San Diego Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year and 2005 US National Entrepreneur of the Year for Health Sciences. In 1998, Peter joined the Sleep Medicine Executive Council at Harvard Medical School, served as vice chairman from 2000 to 2010 and then as chairman from 2010 until 2013. He is on various academic advisory boards including UCSD's Jacobs School of Engineering, where he was named the 2012 Gordon Fellow, UCSD's Rady Business School and the MIT Dean of Engineering's Advisory Council. Peter holds a B.E. with honors in chemical engineering from the University of Sydney, an SM in chemical engineering from MIT, a PhD in bioengineering from the University of Washington, Seattle, and a DSc from UNSW for research which resulted in improved treatment for both hemodialysis and peritoneal dialysis patients.\n\n[Member of the Compensation Committee](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab)\n\n[Member of the Nominating and Corporate Governance Committee](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77)\n\nJames Barlow, MA \n\n![James Barlow](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/12-15-05/James_Barlow_color.jpg?itok=_mXnMdRu)\n\nJames Barlow is a member of the Board of Directors of NAHS Holding, Inc., an Employee Stock Ownership Plan company, whose affiliates provide post-acute care, subacute care, short and long-term rehabilitation, and skilled nursing in the United States. Mr. Barlow is a C-level financial executive with more than 30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations, financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. from January 2002 to March 2015, he oversaw financial due diligence, integration and structuring for all significant asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed Corporation and more than $4.5 billion in other transactions. He ensured consistent application of corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning/forecasting activities. Prior to joining Allergan, Mr. Barlow served as Chief Financial Officer of Wynn Oil Company, a division of Parker Hannifin Corporation, during 2001, Treasurer and Controller of Wynn’s International, Inc. from 1990 to 2000 and Vice President and Controller of Ford Equipment Leasing Company from 1986 to 1990. From 1983 to 1985 Mr. Barlow worked for the accounting firm Deloitte Haskins and Sells. Mr. Barlow received a Bachelor of Science degree in Accounting, graduating magna cum laude, from Brigham Young University and a Master of Accountancy, graduating with honors - high distinction, from Brigham Young University. He is a certified public accountant (inactive).\n\n[Chair of the Audit Committee](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f)\n\n[Member of the Compensation Committee](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab)\n\n[Member of the Nominating and Corporate Governance Committee](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77)\n\nDr. Ed Holmes \n\n![Holmes](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/12-18-42/ed_holmes_color-1.jpg?itok=Xlx-Cak-)\n\nDr. Holmes is currently a Distinguished Professor of Medicine at the University of California, Vice Chancellor/Dean of Health Sciences Emeritus at the University of California, San Diego, and CEO/President of the Sanford Consortium for Regenerative Medicine. He became the Executive Deputy Chairman of the Biomedical Research Council and the Executive Chairman of the National Medical Research Council in Singapore in October 2006; he is currently a Senior Fellow in A*STAR and Advisor to the National Research Council of Singapore. He holds an appointment as the Lien Ying Chow Professor of Medicine at the Yong Loo Lin School of Medicine, National University of Singapore. For his contributions to the Singapore government, Dr. Holmes was made an Honorary Citizen in 2011, and he was awarded the President’s Science and Technology Medal in 2017. Dr. Holmes also served on the Council of Advisors for the National Institute for Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health. He served as Chair of the Research Advisory Board of GlaxoSmithKline, the SAB of Ajinomoto and Board of Directors of Tularik, Inc. He also served on the Grand Challenges Explorations Innovation Review Panel for the Gates Foundation. He has been elected to membership in the American Society for Clinical Investigation, the Association of American Physicians, Fellow of the American Association for the Advancement of Science, and a member of the United States National Academy of Medicine.\n\n[Member of the Audit Committee](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f)\n\n[Chair of the Nominating and Corporate Governance Committee](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77)\n\nDr. Jing L. Marantz, M.D., Ph.D, MBA \n\n![Jing Marantz](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2021/12/13/14-50-56/Jing%20Marantz%20126px.jpg?itok=ZIngFoPN)\n\nJing L. Marantz, MD, PhD, MBA, has over 20 years of experience in the biopharmaceutical industry spanning R&D, business development, and commercial strategy in multiple specialties and rare diseases. She is currently Chief Medical Officer at Scholar Rock, overseeing development and medical affairs. Jing was recently EVP and Chief Business Officer of Krystal Biotech, after serving on its board for a year. Prior to Krystal, she was Senior Vice President of Medical Affairs at Acceleron Pharma until its acquisition by Merck & Co., Inc. Jing has held leadership positions at Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical affairs, and business development. She was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. She received her medical training from Tongji Medical College, a PhD in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.\n\nDr. Magda Marquet \n\n![Magda Marquet](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/12-15-50/Magda_Marquet_color.png?itok=vx1kjOP2)\n\nDr. Marquet is the co-Founder of ALMA Life Sciences, LLC, an early stage investment firm focusing on the creation and growth of innovative healthcare companies with an overall focus on prevention. She is also the co-Founder of AltheaDx, a commercial stage precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression. Dr. Marquet co-founded Althea Technologies in 1998 and led the company to the successful acquisition by Ajinomoto, a global Japanese company, leader in amino acid technology. During her tenure at Althea Technologies, Dr. Marquet had full P&L responsibility and built an organization with R&D and international commercial capabilities. Prior to starting Althea Technologies, Dr. Marquet held several positions in product development and pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals. She currently serves on the following Boards: Pfenex (PFNX) where she is a member of the Governance and Nomination Committee and Arcturus Therapeutics (ARCT) where is the Chairman of the Compensation Committee and a member of the Audit Committee. She also serves on the Board on several private companies such as Senté. As a former founder and CEO, Dr Marquet provides the Board with operational, fund raising expertise including venture, private equity and venture debt. She also brings expertise in M&A, global commercial development and regulatory strategies. She has a passion for building a winning culture of innovation and strategic growth. She holds a Ph.D. in Biochemical Engineering from INSA/University of Toulouse, France. Dr. Marquet has received numerous prestigious awards throughout her career including the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.\n\n[Chair of the Compensation Committee](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab)\n\n[Member of the Audit Committee](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f)\n\nJoseph Payne, MSc \n\n![Joseph Payne, MSc](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/12-17-20/portrait-joseph-e-payne.jpg?itok=mZUj0N_c)\n\nJoseph E. Payne, is the President and Chief Executive Officer of Arcturus Therapeutics, Inc. He serves on Arcturus’s Board since March 2013. He brings with him an exceptional track record of ushering novel therapeutics to the clinic including targeted RNA medicines utilizing lipid-mediated delivery technologies. Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes a Bachelor's Degree in Chemistry, magna cum laude from Brigham Young University, a Master of Science in Synthetic Organic Chemistry from the University of Calgary and Executive Training Certification from MIT Sloan School of Management.\n\nAndy Sassine, MBA \n\n![andy](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2020/01/08/12-18-02/andy_sassine_color2.jpg?itok=P1B3qDbD)\n\nAndy Sassine is currently, and has been since January 2019, the Chief Financial Officer at Arcturus Therapeutics. He also serves on the Board of Directors of Nasdaq listed ICAD Inc. ICAD Inc. is a leading provider of advanced image analysis, workflow solutions and radiation therapy for early detection and treatment of cancer. Mr. Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. Between 2005 and 2011, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund. Mr. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Mr. Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors from 2009 to 2018. Mr. Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.\n\nDr. John Markels \n\n![Dr. John Markels](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2022/12/13/9-01-18/John%20Markels_Website.png?itok=4NyKalSV)\n\nJohn Markels, Ph.D., has over 35 years of leadership experience in the pharmaceutical industry at Merck & Co., Inc., with a deep background in manufacturing, development, and technology transfer as well as global commercial, policy, and organizational development. Currently, he serves on the Board of Sangamo Therapeutics and chairs and serves on the advisory boards for the University of California, Berkeley College of Chemistry and University of Delaware Department of Chemical and Biomolecular Engineering, respectively. Dr. Markels retired from Merck in March 2022, most recently as President of Global Vaccines, a large and growing business where he led an integrated team dedicated to discovery and development, supply and access, and global marketing and long-term strategy for the vaccines portfolio. Earlier roles at Merck included President, Latin America, as well as a long career in senior leadership positions in major regions worldwide in manufacturing technology, operations, supply chain, and strategy. Dr. Markels has worked in every region of the world and lived in the US, Latin America, and Europe. He received his Ph.D. in chemical engineering from the University of California, Berkeley and his B.S. in chemical engineering from the University of Delaware.\n\nDr. Moncef Slaoui \n\n![Dr. Moncef Slaoui](/system/files-encrypted/styles/large/encrypt/nasdaq_kms/people/2024/06/20/13-19-41/Moncef%20Slaoui_Website.png?itok=tAJga_G6)\n\nDr. Moncef Slaoui was the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the operation enabled the fastest ever development, manufacturing, and approval of multiple COVID-19 vaccines in less than 11 months after the virus genetic sequence was described. Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG, and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company.\n\nDr. Slaoui spent nearly 30 years at GlaxoSmithKline (GSK) holding leadership positions including as member of the Board of Directors of GSK PLC; Chairman of Pharmaceutical R&D; Chairman Global R&D, Vaccines & Oncology; and Chairman, Global Vaccines. As Chairman of Pharmaceutical R&D, Dr. Slaoui led a restructuring to improve focus on innovation and productivity. As Chairman of Global Vaccines, Dr. Slaoui was directly involved in GSK's vaccine pipeline, leading to the creation of 14 new vaccines, including Shingrix®, to prevent shingles; Cervarix®, to prevent cervical cancer; Mosquirix, to prevent malaria; Rotarix®, to prevent rotavirus gastroenteritis; and Synflorix, to prevent pneumococcal disease.\n\nIn 2016, Dr. Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world, served on the Advisory Committee to the Director of the NIH from 2011 to 2016, and has advised the U.S. President's Council of Advisors on Science and Technology.\n\nDr. Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles, completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, and was a Professor of Immunology at the University of Mons, Belgium. He received an accelerated Master of Business Administration from IMD, Switzerland in 1998.\n\nSearch * Submit\n"
        },
        {
          "title": "Committee Composition",
          "url": "https://ir.arcturusrx.com/corporate-governance/committee-composition",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Committee Composition \n\n[Audit Committee](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f) | [Compensation Committee](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab) | [Nominating and Corporate Governance Committee](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77)  \n---|---|---  \n[ James Barlow, MA ](/board-member/james-barlow) |  [Audit Committee](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f) |  [Compensation Committee](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab) |  [Nominating and Corporate Governance Committee](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77)  \n[Dr. Peter Farrell ](/board-member/peter-farrell) |  [Compensation Committee](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab) |  [Nominating and Corporate Governance Committee](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77)  \n[ Dr. Ed Holmes ](/board-member/ed-holmes) |  [Audit Committee](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f) |  [Nominating and Corporate Governance Committee](/static-files/5ee8051b-7075-4ab2-a40e-33f30dab1b77)  \n[ Dr. Magda Marquet ](/board-member/magda-marquet) |  [Audit Committee](/static-files/2e54aec9-db77-4568-9f6d-30916c165a4f) |  [Compensation Committee](/static-files/8d771f5a-f891-4b4d-a9d7-90a092ca38ab)  \n  \n= Chairperson = Member\n\nSearch * Submit\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.arcturusrx.com/financial-information/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  SEC Filings \n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -202420232022202120202019201820172016201520142013\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | Filing Group | Issuer | View  \n---|---|---|---|---|---  \nNov 08, 2024 | A statement of beneficial ownership of common stock by certain persons | [SC 13G](/sec-filings/sec-filing/sc-13g/0001140361-24-045812) |  Other | Arcturus Therapeutics Holdings Inc.  |  [0001140361-24-045812.pdf](/static-files/73ba9ffd-a275-479b-91df-4ec3276e95e6) [0001140361-24-045812.rtf](/static-files/33c6cd66-d911-4cb7-89ca-0ffe246b23a2) [0001140361-24-045812.xls](/static-files/de652248-7261-4d83-8a6d-c67183acff4a) [View HTML](/node/12931/html)  \nNov 07, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001193805-24-001318) |  Current Reports | Arcturus Therapeutics Holdings Inc.  |  [0001193805-24-001318.pdf](/static-files/c40b6fa0-838c-46cf-816d-a02294bb3b85) [0001193805-24-001318.rtf](/static-files/46ab8972-4f79-4205-96a1-416ba7202197) [0001193805-24-001318.xls](/static-files/ad820710-c545-49d0-a077-362ee4d070ca) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001193805-24-001318) [View HTML](/node/12921/html)  \nNov 07, 2024 | Quarterly report which provides a continuing view of a company's financial position | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-123469) |  Quarterly Filings | Arcturus Therapeutics Holdings Inc.  |  [0000950170-24-123469.pdf](/static-files/1394f5f3-6d4e-4ecd-ab0f-7ceec83a9168) [0000950170-24-123469.rtf](/static-files/df37c3c8-f7c6-431c-a080-dc2884e1b3bb) [0000950170-24-123469.xls](/static-files/948cad44-ddfd-49e2-b2d9-46a908e941e9) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-123469) [View HTML](/node/12926/html)  \nNov 05, 2024 | A statement of beneficial ownership of common stock by certain persons | [SC 13G](/sec-filings/sec-filing/sc-13g/0001214659-24-018425) |  Other | Arcturus Therapeutics Holdings Inc.  |  [0001214659-24-018425.pdf](/static-files/956d87ec-5c60-46a8-bee1-8e7622d1e362) [0001214659-24-018425.rtf](/static-files/ca1fd735-23c5-4911-b270-013c6aefda8a) [0001214659-24-018425.xls](/static-files/3236f4de-e17c-4a44-8986-6e940ad8f13a) [View HTML](/node/12911/html)  \nOct 16, 2024 | Statement of changes in beneficial ownership of securities | [4](/sec-filings/sec-filing/4/0001193805-24-001248) |  3,4,5 | Arcturus Therapeutics Holdings Inc.  |  [0001193805-24-001248.pdf](/static-files/a6419595-f665-4e91-b33b-8453779e4936) [0001193805-24-001248.rtf](/static-files/77aecf40-77a6-44ce-9ae0-a71abd89caa5) [0001193805-24-001248.xls](/static-files/f0184a53-37a6-4f04-970e-82f38b863df7) [View HTML](/node/12891/html)  \nOct 15, 2024 | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing | [144](/sec-filings/sec-filing/144/0001971857-24-000670) |  Other | Arcturus Therapeutics Holdings Inc.  |  [0001971857-24-000670.pdf](/static-files/2fabca2f-4100-4ee1-8cc8-8fa49a3f7952) [0001971857-24-000670.rtf](/static-files/ed3ae8f4-3f31-47c8-a503-2e1dec6f986b) [View HTML](/node/12886/html)  \nAug 13, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001193805-24-001023) |  Current Reports | Arcturus Therapeutics Holdings Inc.  |  [0001193805-24-001023.pdf](/static-files/e4a65d0c-73f3-406f-b2bd-0708b8a85e7c) [0001193805-24-001023.rtf](/static-files/0d0019a6-eff2-4d7d-a25f-a14b453f4c35) [0001193805-24-001023.xls](/static-files/36dfd784-79e9-490a-b46c-1cc4db0c1461) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001193805-24-001023) [View HTML](/node/12826/html)  \nAug 05, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001193805-24-000990) |  Current Reports | Arcturus Therapeutics Holdings Inc.  |  [0001193805-24-000990.pdf](/static-files/9b82a6c0-9163-4b8a-9096-10c696645ff1) [0001193805-24-000990.rtf](/static-files/0b769bf7-0cde-4074-b721-1cd27a00963c) [0001193805-24-000990.xls](/static-files/7f113f9e-a960-4c24-9f72-543224ec6a1d) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001193805-24-000990) [View HTML](/node/12816/html)  \nAug 05, 2024 | Quarterly report which provides a continuing view of a company's financial position | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-090905) |  Quarterly Filings | Arcturus Therapeutics Holdings Inc.  |  [0000950170-24-090905.pdf](/static-files/2ec88523-93ae-4545-8ca1-34669710f6a8) [0000950170-24-090905.rtf](/static-files/7b3078ec-7b16-4386-8488-3dddcce5388b) [0000950170-24-090905.xls](/static-files/88807e8d-1664-4d6d-95e0-0cf234a7050a) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-090905) [View HTML](/node/12821/html)  \nJul 17, 2024 | Securities offered to employees pursuant to employee benefit plans | [S-8](/sec-filings/sec-filing/s-8/0001193805-24-000937) |  Registration Statements | Arcturus Therapeutics Holdings Inc.  |  [0001193805-24-000937.pdf](/static-files/8fecdb49-c20c-487e-aa82-f3bbeca5966e) [0001193805-24-000937.rtf](/static-files/3e9737e7-2b3f-4746-9793-51ff9f111b30) [0001193805-24-000937.xls](/static-files/1daf81ed-9094-44ce-9b5d-0f14235725c7) [View HTML](/node/12781/html)  \n  \nDisplaying 1 - 10 of 579 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\nSearch * Submit\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://ir.arcturusrx.com/annual-reports",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Annual Reports \n\n## Annual Reports\n\n  * ### 2023 10-K\n\nMarch 14, 2024\n\n[2023 10-K](/static-files/8bce180a-7daa-4c57-8490-361c91585fa2 \"ARCT 10-K 0000950170-24-031156.pdf\") 5.4 MB\n\n  * ### 2022 10-K\n\nMarch 29, 2023\n\n[2022 10-K](/static-files/0631f4bf-d535-4a4d-b3e6-6e22920cee88 \"ARCT Form 10-K.pdf\") 5.6 MB\n\n  * ### 2021 10-K\n\nMarch 1, 2022\n\n[2021 10-K](/static-files/ae5ca859-bbde-4b80-9a42-71363421c912 \"0001564590-22-007832.pdf\") 6.9 MB\n\n  * ### 2020 10-K\n\nMarch 1, 2021\n\n[2020 10-K](/static-files/8df8a350-82cd-4abc-a23f-d26ab7cda418 \"0001564590-21-009872.pdf\") 1.2 MB\n\n  * ### 2019 10-K\n\nMarch 16, 2020\n\n[2019 10-K](/static-files/63dbfb2a-43fa-45bb-ab8b-f87e682d0c0f \"0001564590-20-011037.pdf\") 1.5 MB\n\n  * ### 2018 10-K\n\nMarch 18, 2019\n\n[2018 10-K](/static-files/578f6b4e-88c9-4a97-9f3a-5d4ebfbcc0ae \"0001564590-19-008092.pdf\") 2.9 MB\n\n  * ### 2018 20F \n\nAugust 23, 2018\n\n[20F](/static-files/9f7cf012-386c-434b-861c-298c1eec3ee5 \"0001564590-18-013460.pdf\") 12.6 MB\n\n\n\n\nSearch * Submit\n"
        },
        {
          "title": "Quarterly Results",
          "url": "https://ir.arcturusrx.com/financial-information/quarterly-results",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Quarterly Results \n\n[Show all](#)\n\n## 2024\n\nQ3\n\n  * [Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2024-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-24-123469)\n\n\n\n\nQ2\n\n  * [Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-second-quarter-2024-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-24-090905)\n\n\n\n\nQ1\n\n  * [Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-2024-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-24-055702)\n\n\n\n\n## 2023\n\nQ4\n\n  * [Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress](/static-files/30a28afd-e920-46ba-89b2-c03043459ed5 \"Master Earnings Press release - 3.25.24 that has the astricks Clean copy_.pdf\") 580.8 KB\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0000950170-24-031156)\n\n\n\n\nQ3\n\n  * [Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2023-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-23-063778)\n\n\n\n\nQ2\n\n  * [Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-second-quarter-2023-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-23-039149)\n\n\n\n\nQ1\n\n  * [Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-2023-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-23-019773)\n\n\n\n\n## 2022\n\nQ4\n\n  * [Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-fourth-quarter-2022-financial)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0000950170-23-010380)\n\n\n\n\nQ3\n\n  * [Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2022-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-22-023969)\n\n\n\n\nQ2\n\n  * [Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-second-quarter-2022-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-22-016043)\n\n\n\n\nQ1\n\n  * [Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-2022-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0000950170-22-008524)\n\n\n\n\n## 2021\n\nQ4\n\n  * [Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-fourth-quarter-and-full-year-0)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-22-007832)\n\n\n\n\nQ3\n\n  * [Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2021-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-21-055372)\n\n\n\n\nQ2\n\n  * [Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-second-quarter-2021-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-21-042750)\n\n\n\n\nQ1\n\n  * [Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data](/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-2021-company)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-21-026113)\n\n\n\n\n## 2020\n\nQ4\n\n  * [Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates](/news-releases/news-release-details/arcturus-therapeutics-announces-fourth-quarter-and-full-year)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-21-009872)\n\n\n\n\nQ3\n\n  * [Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data](/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2020-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-20-052527)\n\n\n\n\nQ2\n\n  * [Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update](/news-releases/news-release-details/arcturus-therapeutics-announces-second-quarter-2020-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-20-038980)\n\n\n\n\nQ1\n\n  * [Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update](/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-2020-financial)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-20-023633)\n\n\n\n\n## 2019\n\nQ4\n\n  * [Arcturus Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results](/news-releases/news-release-details/arcturus-therapeutics-reports-fourth-quarter-and-year-end-2019)\n\n  * [Form 10-K](/sec-filings/sec-filing/10-k/0001564590-20-011037)\n\n\n\n\nQ3\n\n  * [Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update](/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-19-042017)\n\n\n\n\nQ2\n\n  * [Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update](/news-releases/news-release-details/arcturus-therapeutics-announces-second-quarter-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-19-032166)\n\n\n\n\nQ1\n\n  * [Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update](/news-releases/news-release-details/arcturus-therapeutics-announces-first-quarter-financial-results)\n\n  * [Form 10-Q](/sec-filings/sec-filing/10-q/0001564590-19-018656)\n\n\n\n\n## 2018\n\nQ4\n\n  * [Arcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results](/news-releases/news-release-details/arcturus-therapeutics-provides-corporate-update-and-reports-0)\n\n\n\n\nQ3\n\n  * [Arcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results](/news-releases/news-release-details/arcturus-therapeutics-provides-corporate-update-and-reports)\n\n\n\n\nQ2\n\n  * [Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update](/news-releases/news-release-details/arcturus-therapeutics-reports-second-quarter-2018-financial)\n\n\n\n\nSearch * Submit\n"
        }
      ]
    },
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.arcturusrx.com/press-releases",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Press Releases \n\nYear: - Any -202420232022202120202019201820172016201520142013\n\n- Any -\n\nItems per page 102550\n\n10\n\n  * November 26, 2024 at 4:01 PM EST\n\n[Summary Toggle](#)[Arcturus Therapeutics to Attend Upcoming Investor Conferences](/news-releases/news-release-details/arcturus-therapeutics-attend-upcoming-investor-conferences-1)\n\nSAN DIEGO --(BUSINESS WIRE)--Nov. 26, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today\n\n[PDF Version](/node/12976/pdf)\n\n  * November 18, 2024 at 8:00 PM EST\n\n[Summary Toggle](#)[Arcturus Therapeutics to Present at Jefferies London Healthcare Conference](/news-releases/news-release-details/arcturus-therapeutics-present-jefferies-london-healthcare)\n\nSAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today\n\n[PDF Version](/node/12956/pdf)\n\n  * November 14, 2024 at 1:00 AM EST\n\n[Summary Toggle](#)[Meiji Seika Pharma Announces Investment in ARCALIS, Inc.](/news-releases/news-release-details/meiji-seika-pharma-announces-investment-arcalis-inc)\n\nTOKYO --(BUSINESS WIRE)--Nov. 14, 2024-- Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan , President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as \" Meiji Seika Pharma \") today announced its investment in ARCALIS, Inc.\n\n[PDF Version](/node/12941/pdf)\n\n  * November 11, 2024 at 4:01 PM EST\n\n[Summary Toggle](#)[Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial](/news-releases/news-release-details/arcturus-therapeutics-receives-clearance-fda-begin-h5n1-pandemic)\n\nSAN DIEGO --(BUSINESS WIRE)--Nov. 11, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today\n\n[PDF Version](/node/12936/pdf)\n\n  * November 7, 2024 at 4:01 PM EST\n\n[Summary Toggle](#)[Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress](/news-releases/news-release-details/arcturus-therapeutics-announces-third-quarter-2024-financial)\n\nCystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with first sale of KOSTAIVE® in Japan KOSTAIVE® European CHMP opinion expected December Positive results from multiple Phase 3 studies support KOSTAIVE® U.S.\n\n[PDF Version](/node/12916/pdf)\n\n  * October 31, 2024 at 4:01 PM EDT\n\n[Summary Toggle](#)[Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024](/news-releases/news-release-details/arcturus-therapeutics-report-third-quarter-financial-results-0)\n\nSAN DIEGO --(BUSINESS WIRE)--Oct. 31, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and\n\n[PDF Version](/node/12896/pdf)\n\n  * September 30, 2024 at 8:00 AM EDT\n\n[Summary Toggle](#)[Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination](/news-releases/news-release-details/self-amplifying-mrna-covid-19-vaccine-demonstrates-superior-0)\n\nHead-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics’ commitment to advancing COVID-19 vaccine innovation to protect public\n\n[PDF Version](/node/12881/pdf)\n\n  * September 13, 2024 at 8:00 AM EDT\n\n[Summary Toggle](#)[Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma](/news-releases/news-release-details/japans-ministry-health-labor-and-welfare-approves-csl-and)\n\nApproval underscores CSL and Arcturus Therapeutics’ commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE ® , the world’s first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, was approved for adults 18 years of\n\n[PDF Version](/node/12866/pdf)\n\n  * September 3, 2024 at 8:30 AM EDT\n\n[Summary Toggle](#)[Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis](/news-releases/news-release-details/arcturus-therapeutics-receives-clearance-investigational-new)\n\nSAN DIEGO --(BUSINESS WIRE)--Sep. 3, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare\n\n[PDF Version](/node/12861/pdf)\n\n  * August 27, 2024 at 5:00 PM EDT\n\n[Summary Toggle](#)[Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences](/news-releases/news-release-details/arcturus-therapeutics-attend-upcoming-investor-scientific-1)\n\nSAN DIEGO --(BUSINESS WIRE)--Aug. 27, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare\n\n[PDF Version](/node/12856/pdf)\n\n\n\n\nDisplaying 1 - 10 of 239 results\n\nSearch * Submit\n"
        },
        {
          "title": "Videos",
          "url": "https://arcturusrx.com/videos/",
          "content": "#  Web server is returning an unknown error Error code 520\n\nVisit [cloudflare.com](https://www.cloudflare.com/5xx-error-landing?utm_source=errorcode_520&utm_campaign=arcturusrx.com) for more information. \n\n2024-11-29 13:46:02 UTC\n\nYou\n\n###  Browser \n\nWorking\n\n[ ](https://www.cloudflare.com/5xx-error-landing?utm_source=errorcode_520&utm_campaign=arcturusrx.com)\n\nMumbai\n\n###  [ Cloudflare ](https://www.cloudflare.com/5xx-error-landing?utm_source=errorcode_520&utm_campaign=arcturusrx.com)\n\nWorking\n\narcturusrx.com\n\n###  Host \n\nError\n\n## What happened?\n\nThere is an unknown connection issue between Cloudflare and the origin web server. As a result, the web page can not be displayed.\n\n## What can I do?\n\n### If you are a visitor of this website:\n\nPlease try again in a few minutes.\n\n### If you are the owner of this website:\n\nThere is an issue between Cloudflare's cache and your origin web server. Cloudflare monitors for these errors and automatically investigates the cause. To help support the investigation, you can pull the corresponding error log from your web server and submit it our support team. Please include the Ray ID (which is at the bottom of this error page). [Additional troubleshooting resources](https://support.cloudflare.com/hc/en-us/articles/200171936-Error-520).\n\nCloudflare Ray ID: **8ea30aa12ea7406f** • Your IP: Click to reveal 183.87.252.47 • Performance & security by [Cloudflare](https://www.cloudflare.com/5xx-error-landing?utm_source=errorcode_520&utm_campaign=arcturusrx.com)\n"
        },
        {
          "title": "Media Coverage",
          "url": "https://ir.arcturusrx.com/media-coverage",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Media Coverage \n\nCategories Publication/Posters\n\nYear None202420232022202120202019201820172016201520142013\n\nNone\n\n[Cystic Fibrosis News Today “ARCT-032, therapy for all with CF, showing safety i…](https://cysticfibrosisnewstoday.com/news/arct-032-inhaled-cf-treatment-showing-safety-phase-1-trial/)\n\nJune 12, 2024\n\n[ENDPOINTS NEWS “Arcturus teases data from small trial of inhalable cystic fibro…](https://endpts.com/arcturus-teases-data-from-small-trial-of-inhalable-cystic-fibrosis-mrna-therapy-stock-rockets/)\n\nMay 29, 2024\n\n[Nature Communications “Safety, immunogenicity and efficacy of the self-amplifyi…](https://www.nature.com/articles/s41467-024-47905-1)\n\nMay 14, 2024\n\n[Notice concerning Positive Results of Phase III Study of Bivalent Version of Ko…](https://www.meiji.com/global/news/2024/pdf/240319_01.pdf)\n\nMarch 19, 2024\n\n[MIT Technology Review “The next generation of mRNA vaccines is on its way”](https://www.technologyreview.com/2024/02/02/1087536/the-next-generation-of-mrna-vaccines-is-on-its-way/)\n\nFebruary 2, 2024\n\n[BioPharm, International “Increasing mRNA Product Stability with Lyophilization”](https://www.biopharminternational.com/view/increasing-mrna-product-stability-with-lyophilization)\n\nJanuary 31, 2024\n\n[Science Magazine “The First Self-Amplifying mRNA Vaccine”](https://www.science.org/content/blog-post/first-self-amplifying-mrna-vaccine)\n\nJanuary 25, 2024\n\n[Genetic Engineering & Biotechnology News “Self-Replicating RNA Manufacturer Cre…](https://www.genengnews.com/topics/bioprocessing/self-replicating-rna-manufacturer-credits-perfecting-the-bioprocess/)\n\nJanuary 18, 2024\n\n[Nature “Self-copying RNA vaccine wins first full approval: what’s next?”](https://www.nature.com/articles/d41586-023-03859-w)\n\nDecember 6, 2023\n\n[San Diego Business Journal “Arcturus Lands $9M for Inhaled mRNA CF Treatment”](https://www.sdbj.com/life-sciences/pharmaceuticals/arcturus-lands-9m-for-inhaled-mrna-cf-treatment/)\n\nOctober 10, 2023\n\nDisplaying 1 - 10 of 105 \n\n![Arcturus-Covid19 Message.jpg](/system/files-encrypted/nasdaq_kms/inline-images/Combined%20Tower%20Images%201628px.jpg) ![Nasdaq combined](/system/files-encrypted/nasdaq_kms/inline-images/Arcturus_Nasdaq%20Tower%20photo_1-5%20yr.PNG)\n\nSearch * Submit\n"
        },
        {
          "title": "Presentations",
          "url": "https://ir.arcturusrx.com/presentations",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Presentations \n\n  * ### Corporate Deck\n\nFebruary 1, 2050\n\n[Corporate Deck November 2024](/static-files/198c6d28-bb6b-4162-a7a6-5854a0fd2d6c \"ARCT Corporate Deck Nov 2024 latest version.pdf\") 2 MB\n\n  * ### 47th Annual Cystic Fibrosis Conference\n\nJune 7, 2024\n\n[47th Annual Cystic Fibrosis Conference](/static-files/be6e3d0a-72da-47d8-a0d4-01709b55ea60 \"47th Annual Cystic Fibrosis Conference__ECFS2024.pdf\") 1.5 MB\n\n  * ### April 2024- 45th Annual Society for Inherited Metabolic Disorders\n\nApril 17, 2024\n\n[April 2024- 45th Annual Society for Inherited Metabolic Disorders](/static-files/ae0913e7-e3a8-4f83-9572-ac28c7d6df90 \"SIMD Slides 4-17-2024.pdf\") 1.1 MB\n\n  * ### January 2024- 42nd Annual J.P. Morgan Healthcare Conference\n\nJanuary 14, 2024\n\n[January 2024- 42nd Annual J.P. Morgan Healthcare Conference](/static-files/78d7a23c-f7a6-4504-ae49-2fa68d587d78 \"January 2024- 42nd Annual J.P. Morgan Healthcare Conference.pdf\") 2.9 MB\n\n  * ### November 2023-mRNA Health Conference: Self-amplifying RNA platform\n\nNovember 3, 2023\n\n[November 2023-mRNA Health Conference: Self-amplifying RNA platform](/static-files/bd49363d-3ee8-4335-bfe8-9432ca09340a \"November 2023-mRNA Health Conference_Self-amplifying RNA platform.pdf\") 2.3 MB\n\n  * ### April 2023- 18th Annual Global Hepatitis Summit: LUNAR-HBV \n\nApril 4, 2023\n\n[April 2023- 18th Annual Global Hepatitis Summit: LUNAR-HBV ](/static-files/e3e6b7e5-ce45-41c3-b357-9eeeed455b5c \"LUNAR-HBV Global Hepatitis Summit 2023.pdf\") 1.2 MB\n\n  * ### 4Q22 Earnings Call Transcript\n\nMarch 27, 2023\n\n[4Q22 Earnings Call Transcript](/static-files/7324ce7a-ece6-48fe-a722-d441cdb26b7d \"4Q22 Earnings Script Final.pdf\") 185 KB\n\n  * ### January 2023- 41st Annual J.P. Morgan Healthcare Conference\n\nJanuary 9, 2023\n\n[January 2023- 41st Annual J.P. Morgan Healthcare Conference](/static-files/0f0cec25-2158-4251-8105-a1faca06e88f \"JPM 1-10-2022 v3.pdf\") 2.8 MB\n\n  * ### March 2021—Conference Call\n\nFebruary 25, 2021\n\n[March 2021—Conference Call](/static-files/a84f62c6-a9d8-457b-baab-3c02f6bab6ef \"Professor Ooi Eng Eong slides Duke-NUS.pdf\") 564.1 KB\n\n  * ### December 2020- Conference Call\n\nDecember 28, 2020\n\n[December 2020- Conference Call](/static-files/7f1f7674-71b0-4276-8b88-339c3e51b671 \"Combined slides of Joe Steve EEO 12-28-2020 webcasted.pdf\") 4.3 MB\n\n  * ### November 2020 - mRNA Health Conference: LUNAR-COV19 Prophylactic Vaccine\n\nNovember 16, 2020\n\n[November 2020 - mRNA Health Conference: LUNAR-COV19 Prophylactic Vaccine](/static-files/8cd75184-e5ed-4ca0-8924-f2410cede49c \"LUNAR CoV-19 Vaccine International mRNA Health Conference V.4_November 2020.pdf\") 1.5 MB\n\n  * ### September 2020-ASGCT\n\nOctober 2, 2020\n\n[September 2020-ASGCT](/static-files/63f64ff5-b70d-492b-91c8-11a6ecd6cbf8 \"ASCGT Poster presentation_Sean Sullivan_Sep2020.pdf\") 786.8 KB\n\n  * ### September 2020 – Tides Presentation\n\nAugust 31, 2020\n\n[September 2020 – Tides Presentation](/static-files/5f0c040f-872c-4e16-82ce-523ff083b708 \"TIDES 2020 Development of a self-transcribing and replicating \\(STARR™\\) mRNA vaccine candidate against SARS-CoV-2 .pdf\") 2.5 MB\n\n  * ### May 2020 - ASGCT\n\nApril 16, 2020\n\n[May 2020 - ASGCT](/static-files/a1f7a633-ea67-4b84-9867-2daa07587490 \"May 2020--ASGCT.pdf\") 3.1 MB\n\n  * ### May 2019 -TIDES Presentation\n\nMay 20, 2019\n\n[May 2019 - TIDES Presentation](/static-files/72acee75-e805-4edf-8d55-1545698964cb \"May 2019 --TIDES Presentation.pdf\") 3.9 MB\n\n  * ### November 2018 - mRNA Health Conference: Enabling Delivery of mRNA Therapeutics and Vaccines\n\nNovember 15, 2018\n\n[November 2018 - mRNA Health Conference: Enabling Delivery of mRNA Therapeutics and Vaccines](/static-files/229662a5-08e0-421e-87b8-26cf1e587e54 \"11-15-2018 V1.pdf\") 3.1 MB\n\n\n\n\nSearch * Submit\n"
        },
        {
          "title": "Events",
          "url": "https://ir.arcturusrx.com/investor-calendar",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Events \n\n## Upcoming Events\n\nDec 3, 2024 at 4:30 PM EST \n\n### \n\n[Piper Sandler 36th Annual Healthcare Conference (Fireside Chat)](/events/event-details/piper-sandler-36th-annual-healthcare-conference-fireside-chat)\n\n[Webcast Link](https://event.webcasts.com/starthere.jsp?ei=1699745&tp_key=eca61c2a00)\n\nDec 4, 2024 \n\n###  Citi’s 2024 Global Healthcare Conference (Attending) \n\nDec 5, 2024 at 8:45 AM EST \n\n###  7th Annual Evercore HealthCONx Conference (Fireside Chat) \n\n## Past Events\n\nYear None2024202320222021202020192018201720162015\n\n2024\n\nNov 20, 2024 at 9:30 AM GMT \n\n### \n\n[Jefferies London Healthcare Conference | Presentation](https://wsw.com/webcast/jeff315/arct/1842120)\n\n[Webcast link](https://wsw.com/webcast/jeff315/arct/1842120)\n\nNov 13, 2024 at 4:00 PM EST \n\n### \n\n[Guggenheim Healthcare Innovation Conference | Fireside Chat](https://wsw.com/webcast/guggen/register.aspx?conf=guggen&page=arct&url=https%3A//wsw.com/webcast/guggen/arct/1936290)\n\n[Webcast link](https://wsw.com/webcast/guggen/register.aspx?conf=guggen&page=arct&url=https%3A//wsw.com/webcast/guggen/arct/1936290)\n\nNov 7, 2024 at 4:30 PM EST \n\n### \n\n[Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024](https://viavid.webcasts.com/starthere.jsp?ei=1690364&tp_key=aa4eb0ba02)\n\n[Webcast link](https://viavid.webcasts.com/starthere.jsp?ei=1690364&tp_key=aa4eb0ba02)\n\nSep 18, 2024 at 8:00 AM EDT \n\n### \n\n[Cantor Fitzgerald Annual Healthcare Conference | Fireside Chat](https://wsw.com/webcast/cantor22/arct/2078190)\n\n[Webcast link](https://wsw.com/webcast/cantor22/arct/2078190)\n\nSep 9, 2024 at 11:00 AM EDT \n\n### \n\n[H.C. Wainwright 26th Annual Global Investment Conference | Presentation](https://journey.ct.events/view/a219bc5c-de67-401e-a797-1cb25d203b01)\n\n[Webcast link](https://journey.ct.events/view/a219bc5c-de67-401e-a797-1cb25d203b01)\n\nSep 5, 2024 at 2:15 PM EDT \n\n###  RNA Leaders USA Congress | Presentation \n\nSep 4, 2024 at 3:00 PM EDT \n\n### \n\n[Wells Fargo 2024 Healthcare Conference | Fireside Chat](https://event.webcasts.com/starthere.jsp?ei=1683315&tp_key=6c8ea33183&tp_special=8)\n\n[Webcast link](https://event.webcasts.com/starthere.jsp?ei=1683315&tp_key=6c8ea33183&tp_special=8)\n\nAug 13, 2024 at 9:30 AM EDT \n\n### \n\n[Canaccord Genuity 44th Annual Growth Conference | Presentation](https://wsw.com/webcast/canaccord98/arct/2454870)\n\n[Webcast link](https://wsw.com/webcast/canaccord98/arct/2454870)\n\nAug 5, 2024 at 4:30 PM EDT \n\n### \n\n[Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024](https://viavid.webcasts.com/starthere.jsp?ei=1680373&tp_key=c4beaed576)\n\n[Webcast link](https://viavid.webcasts.com/starthere.jsp?ei=1680373&tp_key=c4beaed576)\n\nJun 12, 2024 at 2:40 PM EDT \n\n###  Goldman Sachs 45th Annual Healthcare Conference | Fireside Chat \n\nSearch * Submit\n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Stock Quote",
          "url": "https://ir.arcturusrx.com/stock-information/stock-quote",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Stock Quote \n\nArcturus’s investor relations team is happy to answer any shareholder questions. You may contact Arcturus’s investor relations by phone at 858-900-2666 or by email at IR@ArcturusRx.com.\n\n    Change\n    Volume\n    Today's Open\n    Previous Close\n\n    Today's High\n    Today's Low\n    52 Week High\n    52 Week Low\n\nMinimum 15 minutes delayed. Source: LSEG\n\nSearch * Submit\n"
        },
        {
          "title": "Historical Price Lookup",
          "url": "https://ir.arcturusrx.com/stock-information/historical-price-lookup",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Historical Price Lookup \n\nThe historic price lookup for Arcturus Therapeutics Ltd. starts November 20th, 2017.\n\nLookup Month JanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember\n\nNovember\n\nLookup Day 12345678910111213141516171819202122232425262728293031\n\n29\n\nLookup Year 20172018201920202021202220232024\n\n2024\n\nLeave this field blank\n\n## Week of November 25, 2024\n\nDate Requested | Closing Price | Volume | Split Adjustment Factor | Open Price | Day High | Day Low  \n---|---|---|---|---|---|---  \nNovember 25, 2024 | $17.58 | 598,977 | 1:1 | $17.41 | $18.31 | $17.32  \nNovember 26, 2024 | $16.93 | 281,038 | 1:1 | $17.53 | $17.83 | $16.83  \nNovember 27, 2024 | $17.51 | 231,533 | 1:1 | $17.13 | $17.71 | $16.92  \n  \nNOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. The closing price is not necessarily indicative of future price performance.\n\nMinimum 15 minutes delayed. Source: LSEG\n\nSearch * Submit\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://ir.arcturusrx.com/financial-information/analyst-coverage",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Analyst Coverage \n\nAnalysts | Firm  \n---|---  \nWhitney Ijem  |  Canaccord Genuity  \nPete Stavropoulos  |  Cantor  \nYigal Nochomovitz  |  Citi  \nSeamus Fernandez  |  Guggenheim  \nEd Arce  |  HCW  \nYale Jen  |  Laidlaw  \nLili Nsongo  |  Leerink Partners  \nYasmeen Rahimi  |  Piper Sandler  \nYanan Zhu  |  Wells Fargo  \nMyles Minter  |  William Blair  \n  \nArcturus Therapeutics, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Arcturus Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Arcturus Therapeutics, Inc. or its management. Arcturus Therapeutics, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n\nSearch * Submit\n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "Investor FAQ",
          "url": "https://ir.arcturusrx.com/shareholder-services/investor-faq",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Investor FAQ \n\nArcturus’s investor relations team is happy to answer any shareholder questions. You may contact Arcturus’s investor relations by phone at 858-900-2682 or by email at IR@ArcturusRx.com.\n\n[Show All](#)\n\nWhat is Arcturus's business focus?\n\nArcturus Therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines.\n\nWhere can I find additional information about Arcturus?\n\nInformation can be accessed directly through the Company’s website ([http://www.arcturusrx.com](http://www.arcturusrx.com/)). Annual reports on Form 20-F, periodic reports on Form 6-K, and other filings with the SEC can be accessed directly through the Arcturus website or through the Securities and Exchange Commission’s website at [http://www.sec.gov](http://www.sec.gov/).\n\nWhere is Arcturus headquartered?\n\n10628 Science Center Drive, Suite 250 San Diego, CA 92121\n\nWhat is Arcturus's trading symbol?\n\nArcturus ordinary shares trade under the symbol “ARCT.”\n\nWhere do Arcturus's ordinary shares trade?\n\nShares of Arcturus trade on The NASDAQ Global Market.\n\nHow many ordinary shares of Arcturus are outstanding?\n\nThe total number of shares outstanding for Arcturus can be found in Arcturus’s filings with the SEC at [http://www.sec.gov](http://www.sec.gov/) and are also available at <http://www.arcturusrx.com>.\n\nWhen is the fiscal year end for Arcturus?\n\nArcturus’s fiscal year end is December 31st.\n\nDoes Arcturus offer a Direct Stock Purchase Plan?\n\nNo, Arcturus does not offer a Direct Stock Purchase Plan at this time.\n\nDoes Arcturus pay a dividend?\n\nArcturus does not currently intend to declare distributions on its shares in the foreseeable future.\n\nWho is Arcturus's transfer agent and how does a registered shareholder contact the agent regarding account information?\n\nContinental Stock Transfer & Trust Company Mail/overnight address: 17 Battery Place, 8th Floor New York, NY 10004 Phone: +1 800.509.5586\n\nWho is Arcturus's independent auditor?\n\nArcturus’s independent auditor is Ernst & Young LLP.\n\nHow do I contact Investor Relations?\n\nArcturus’s investor relations team is happy to answer any shareholder questions. You may contact Arcturus’s investor relations by phone at 858-900-2682 or by email at IR@ArcturusRx.com.\n\n[Show all](#)\n\nWhat is Arcturus's business focus?\n    Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system (LUNAR™) and UNA Oligomer chemistry technologies.\nWhere can I find additional information about Arcturus?\n    Information can be accessed directly through the Company’s website ([http://www.arcturusrx.com](http://www.arcturusrx.com/)). Annual reports on Form 20-F, periodic reports on Form 6-K, and other filings with the SEC can be accessed directly through the Arcturus website or through the Securities and Exchange Commission’s website at [http://www.sec.gov](http://www.sec.gov/).\nWhere is Arcturus headquartered?\n    10628 Science Center Drive, Suite 250 San Diego, CA 92121\nWhat is Arcturus's trading symbol?\n    Arcturus ordinary shares trade under the symbol “ARCT.”\nWhere do Arcturus's ordinary shares trade?\n    Shares of Arcturus trade on The NASDAQ Global Market.\nHow many ordinary shares of Arcturus are outstanding?\n    The total number of shares outstanding for Arcturus can be found in Arcturus’s filings with the SEC at [http://www.sec.gov](http://www.sec.gov/) and are also available at <http://www.arcturusrx.com>.\nWhen is the fiscal year end for Arcturus?\n    Arcturus’s fiscal year end is December 31st.\nDoes Arcturus offer a Direct Stock Purchase Plan?\n    No, Arcturus does not offer a Direct Stock Purchase Plan at this time.\nDoes Arcturus pay a dividend?\n    Arcturus does not currently intend to declare distributions on its shares in the foreseeable future.\nWho is Arcturus's transfer agent and how does a registered shareholder contact the agent regarding account information?\n    Continental Stock Transfer & Trust Company Mail/overnight address: 17 Battery Place, 8th Floor New York, NY 10004 Phone: +1 800.509.5586\nWho is Arcturus's independent auditor?\n    Arcturus’s independent auditor is Ernst & Young LLP.\nHow do I contact Investor Relations?\n    Arcturus’s investor relations team is happy to answer any shareholder questions. You may contact Arcturus’s investor relations by phone at 858-900-2666 or by email at IR@ArcturusRx.com.\n\nSearch * Submit\n"
        },
        {
          "title": "Contact IR",
          "url": "https://ir.arcturusrx.com/shareholder-services/contact-ir",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Contact IR \n\nArcturus’s investor relations team is happy to answer any shareholder questions. You may contact Arcturus’s investor relations by phone at 858-900-2660 or by email at IR@ArcturusRx.com.\n\nMaterial Selections\n\nInvestor Kit\n\nFirst Name\n\nLast Name\n\nEmail *\n\nTitle\n\nCompany\n\nInvestor Type - None -Individual InvestorBuy-Side AnalystSell-Side AnalystPortfolio ManagerStock BrokerEmployeeNews MediaLibraryOther\n\n- None -\n\nAddress\n\nCountry - None -AfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCôte d’IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRéunionRomaniaRussiaRwandaSamoaSan MarinoSão Tomé & PríncipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkeyTurkmenistanTurks & Caicos IslandsTuvaluU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabwe\n\n- None -\n\nWork Phone\n\nFax\n\nHome Phone\n\nComments\n\nLeave this field blank\n\nSearch * Submit\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://ir.arcturusrx.com/shareholder-services/email-alerts",
          "content": "[ Skip to main navigation ](#main-menu)\n\n#  Email Alerts \n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nNews  \nWeekly Summary  \n  \nEmail *\n\nLeave this field blank\n\nSearch * Submit\n"
        }
      ]
    }
  ]
}